Drug application
BYDUREON BCISE (EXENATIDE SYNTHETIC)
Drugs@FDA NDA 209210 · ASTRAZENECA AB
Key facts
| Drug name | BYDUREON BCISE |
|---|---|
| Active ingredients | EXENATIDE SYNTHETIC |
| Application type | NDA |
| Application number | 209210 |
| Company | ASTRAZENECA AB |
| Dosage forms | SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS |
| Strength | 2MG/0.85ML (2MG/0.85ML) |
| Marketing status | Discontinued |
| Reference listed drug | Yes |
| Latest submission class | Type 3 - New Dosage Form |
| Latest submission status date | Oct 20, 2017 |
At a glance
- 1–9 Submissions
- 10–99 Supplements
- 10–99 Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: